Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
Aquestive Therapeutics Inc (NASDAQ: AQST) closed the day trading at $3.86 down -3.02% from the previous closing price of $3.98. In other words, the price has decreased by -$3.02 from its previous closing price. On the day, 0.95 million shares were traded. AQST stock price reached its highest trading level at $3.985 during the session, while it also had its lowest trading level at $3.85.
Ratios:
For a better understanding of AQST, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.18 and its Current Ratio is at 3.53.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $17. On May 10, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $8.Leerink Partners initiated its Outperform rating on May 10, 2024, with a $8 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 26 ’24 when Jung Cassie sold 44 shares for $4.87 per share. The transaction valued at 214 led to the insider holds 0 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AQST now has a Market Capitalization of 481473216 and an Enterprise Value of 364655232. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.58. Its current Enterprise Value per Revenue stands at 8.263 whereas that against EBITDA is -7.013.
Stock Price History:
The Beta on a monthly basis for AQST is 1.82, which has changed by -0.16630667 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, AQST has reached a high of $5.80, while it has fallen to a 52-week low of $2.12. The 50-Day Moving Average of the stock is 1.03%, while the 200-Day Moving Average is calculated to be 13.22%.
Shares Statistics:
Over the past 3-months, AQST traded about 1.38M shares per day on average, while over the past 10 days, AQST traded about 1916080 shares per day. A total of 120.97M shares are outstanding, with a floating share count of 111.19M. Insiders hold about 8.09% of the company’s shares, while institutions hold 37.58% stake in the company. Shares short for AQST as of 1753920000 were 9442487 with a Short Ratio of 6.84, compared to 1751241600 on 11181713. Therefore, it implies a Short% of Shares Outstanding of 9442487 and a Short% of Float of 11.2799995.
Earnings Estimates
Investors are keenly observing as 2.0 analysts analyze and rate the current performance of Aquestive Therapeutics Inc (AQST) in the stock market.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.12 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.56 and -$0.6 for the fiscal current year, implying an average EPS of -$0.58. EPS for the following year is -$0.52, with 2.0 analysts recommending between -$0.4 and -$0.65.
Revenue Estimates
A total of 9 analysts have provided revenue estimates for AQST’s current fiscal year. The highest revenue estimate was $50.9M, while the lowest revenue estimate was $18.72M, resulting in an average revenue estimate of $41.99M. In the same quarter a year ago, actual revenue was $57.56MBased on 9 analysts’ estimates, the company’s revenue will be $60.67M in the next fiscal year. The high estimate is $77M and the low estimate is $31.58M.
